Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer Announced
“We are extremely excited about the updated combination study protocol and grateful for the significantly expanded support from Eli Lilly to run the trial,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “As we expected, and the preliminary EVANGELINE data has confirmed, the 80 mg dose of (Z)-endoxifen has a highly favorable safety profile and delivers the desired concentration levels to optimally target PKCβ1. We also know from both the 40 mg and 80 mg EVANGELINE cohorts that premenopausal women treated with (Z)-endoxifen experience profound clinical benefit without the need for ovarian suppression. Further validating this with a head-to-head comparison of data from the two cohorts in the combination study will be extremely valuable as we continue conversations with prospective partners and regulators.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.